Executive Summary
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsSmith Interface Technologies, LLC
Apple Inc. successfully obtained institution at the PTAB against Smith Interface Technologies, LLC regarding claims related to Graphical User Interfaces (GUIs). The Board found a reasonable likelihood of obviousness over prior art references Shiplacoff and Nan, leading to an institutional decision.
Samsung Electronics Co., Ltd. et al.vsHarbor Island Dynamic, LLC
The PTAB issued a Final Written Decision finding all 18 challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully demonstrated anticipation under § 102 and obviousness under § 103, primarily using prior art reference Cooney.
Google LLCvsDialect LLC
The PTAB found that claims 1-7, 12-17, and 19-23 were unpatentable over prior art (Coffman/Kennewick/Lee) based on obviousness. The Board adopted the Petitioner's view that 'synchronize' only requires updating context information without duplicating entry order.
Dexcom, Inc.vsAbbott Diabetes Care Inc.
Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.
Hecht, ThomasvsCarver Edison, Inc.
Petitioner Thomas Hecht filed an IPR challenging 18 claims of U.S. Patent No. 10,445,833, arguing the methods for maximizing ESPP shares are obvious over prior art combining financial and computer technology.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.